GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts

Michel Bernier, Jonathan Catazaro, Nagendra S. Singh, Artur Wnorowski, Anna Boguszewska-Czubara, Krzysztof Jozwiak, Robert Powers, Irving W. Wainer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Warburg effect is a predominant metabolic pathway in cancer cells characterized by enhanced glucose uptake and its conversion to l-lactate and is associated with upregulated expression of HIF-1α and activation of the EGFR-MEK-ERK, Wnt-β-catenin, and PI3K-AKT signaling pathways. (R,R′)-4′-methoxy-1-naphthylfenoterol ((R,R′)-MNF) significantly reduces proliferation, survival, and motility of PANC-1 pancreatic cancer cells through inhibition of the GPR55 receptor. We examined (R,R′)-MNF's effect on glycolysis in PANC-1 cells and tumors. Global NMR metabolomics was used to elucidate differences in the metabolome between untreated and (R,R′)-MNF-treated cells. LC/MS analysis was used to quantify intracellular concentrations of β-hydroxybutyrate, carnitine, and l-lactate. Changes in target protein expression were determined by Western blot analysis. Data was also obtained from mouse PANC-1 tumor xenografts after administration of (R,R′)-MNF. Metabolomics data indicate that (R,R′)-MNF altered fatty acid metabolism, energy metabolism, and amino acid metabolism and increased intracellular concentrations of β-hydroxybutyrate and carnitine while reducing l-lactate content. The cellular content of phosphoinositide-dependent kinase-1 and hexokinase 2 was reduced consistent with diminished PI3K-AKT signaling and glucose metabolism. The presence of the GLUT8 transporter was established and found to be attenuated by (R,R′)-MNF. Mice treated with (R,R′)-MNF had significant accumulation of l-lactate in tumor tissue relative to vehicle-treated mice, together with reduced levels of the selective l-lactate transporter MCT4. Lower intratumoral levels of EGFR, pyruvate kinase M2, β-catenin, hexokinase 2, and p-glycoprotein were also observed. The data suggest that (R,R′)-MNF reduces glycolysis in PANC-1 cells and tumors through reduced expression and function at multiple controlling sites in the glycolytic pathway.

Original languageEnglish (US)
Pages (from-to)2131-2142
Number of pages12
JournalInternational Journal of Cancer
Volume141
Issue number10
DOIs
StatePublished - Nov 15 2017

Fingerprint

Tumor Cell Line
Pancreatic Neoplasms
Heterografts
Lactic Acid
Hydroxybutyrates
Catenins
Hexokinase
Metabolomics
Carnitine
Glycolysis
Neoplasms
Phosphatidylinositol 3-Kinases
Monocarboxylic Acid Transporters
Glucose
Pyruvate Kinase
1-Phosphatidylinositol 4-Kinase
Metabolome
Mitogen-Activated Protein Kinase Kinases
Metabolic Networks and Pathways
Energy Metabolism

Keywords

  • PKM2
  • Warburg effect
  • l-lactate
  • metabolic reprogramming
  • metabolomics
  • pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bernier, M., Catazaro, J., Singh, N. S., Wnorowski, A., Boguszewska-Czubara, A., Jozwiak, K., ... Wainer, I. W. (2017). GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. International Journal of Cancer, 141(10), 2131-2142. https://doi.org/10.1002/ijc.30904

GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. / Bernier, Michel; Catazaro, Jonathan; Singh, Nagendra S.; Wnorowski, Artur; Boguszewska-Czubara, Anna; Jozwiak, Krzysztof; Powers, Robert; Wainer, Irving W.

In: International Journal of Cancer, Vol. 141, No. 10, 15.11.2017, p. 2131-2142.

Research output: Contribution to journalArticle

Bernier, M, Catazaro, J, Singh, NS, Wnorowski, A, Boguszewska-Czubara, A, Jozwiak, K, Powers, R & Wainer, IW 2017, 'GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts', International Journal of Cancer, vol. 141, no. 10, pp. 2131-2142. https://doi.org/10.1002/ijc.30904
Bernier M, Catazaro J, Singh NS, Wnorowski A, Boguszewska-Czubara A, Jozwiak K et al. GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. International Journal of Cancer. 2017 Nov 15;141(10):2131-2142. https://doi.org/10.1002/ijc.30904
Bernier, Michel ; Catazaro, Jonathan ; Singh, Nagendra S. ; Wnorowski, Artur ; Boguszewska-Czubara, Anna ; Jozwiak, Krzysztof ; Powers, Robert ; Wainer, Irving W. / GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts. In: International Journal of Cancer. 2017 ; Vol. 141, No. 10. pp. 2131-2142.
@article{6cb309a9768d4283901f22d7bdcd656e,
title = "GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts",
abstract = "The Warburg effect is a predominant metabolic pathway in cancer cells characterized by enhanced glucose uptake and its conversion to l-lactate and is associated with upregulated expression of HIF-1α and activation of the EGFR-MEK-ERK, Wnt-β-catenin, and PI3K-AKT signaling pathways. (R,R′)-4′-methoxy-1-naphthylfenoterol ((R,R′)-MNF) significantly reduces proliferation, survival, and motility of PANC-1 pancreatic cancer cells through inhibition of the GPR55 receptor. We examined (R,R′)-MNF's effect on glycolysis in PANC-1 cells and tumors. Global NMR metabolomics was used to elucidate differences in the metabolome between untreated and (R,R′)-MNF-treated cells. LC/MS analysis was used to quantify intracellular concentrations of β-hydroxybutyrate, carnitine, and l-lactate. Changes in target protein expression were determined by Western blot analysis. Data was also obtained from mouse PANC-1 tumor xenografts after administration of (R,R′)-MNF. Metabolomics data indicate that (R,R′)-MNF altered fatty acid metabolism, energy metabolism, and amino acid metabolism and increased intracellular concentrations of β-hydroxybutyrate and carnitine while reducing l-lactate content. The cellular content of phosphoinositide-dependent kinase-1 and hexokinase 2 was reduced consistent with diminished PI3K-AKT signaling and glucose metabolism. The presence of the GLUT8 transporter was established and found to be attenuated by (R,R′)-MNF. Mice treated with (R,R′)-MNF had significant accumulation of l-lactate in tumor tissue relative to vehicle-treated mice, together with reduced levels of the selective l-lactate transporter MCT4. Lower intratumoral levels of EGFR, pyruvate kinase M2, β-catenin, hexokinase 2, and p-glycoprotein were also observed. The data suggest that (R,R′)-MNF reduces glycolysis in PANC-1 cells and tumors through reduced expression and function at multiple controlling sites in the glycolytic pathway.",
keywords = "PKM2, Warburg effect, l-lactate, metabolic reprogramming, metabolomics, pancreatic cancer",
author = "Michel Bernier and Jonathan Catazaro and Singh, {Nagendra S.} and Artur Wnorowski and Anna Boguszewska-Czubara and Krzysztof Jozwiak and Robert Powers and Wainer, {Irving W.}",
year = "2017",
month = "11",
day = "15",
doi = "10.1002/ijc.30904",
language = "English (US)",
volume = "141",
pages = "2131--2142",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - GPR55 receptor antagonist decreases glycolytic activity in PANC-1 pancreatic cancer cell line and tumor xenografts

AU - Bernier, Michel

AU - Catazaro, Jonathan

AU - Singh, Nagendra S.

AU - Wnorowski, Artur

AU - Boguszewska-Czubara, Anna

AU - Jozwiak, Krzysztof

AU - Powers, Robert

AU - Wainer, Irving W.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - The Warburg effect is a predominant metabolic pathway in cancer cells characterized by enhanced glucose uptake and its conversion to l-lactate and is associated with upregulated expression of HIF-1α and activation of the EGFR-MEK-ERK, Wnt-β-catenin, and PI3K-AKT signaling pathways. (R,R′)-4′-methoxy-1-naphthylfenoterol ((R,R′)-MNF) significantly reduces proliferation, survival, and motility of PANC-1 pancreatic cancer cells through inhibition of the GPR55 receptor. We examined (R,R′)-MNF's effect on glycolysis in PANC-1 cells and tumors. Global NMR metabolomics was used to elucidate differences in the metabolome between untreated and (R,R′)-MNF-treated cells. LC/MS analysis was used to quantify intracellular concentrations of β-hydroxybutyrate, carnitine, and l-lactate. Changes in target protein expression were determined by Western blot analysis. Data was also obtained from mouse PANC-1 tumor xenografts after administration of (R,R′)-MNF. Metabolomics data indicate that (R,R′)-MNF altered fatty acid metabolism, energy metabolism, and amino acid metabolism and increased intracellular concentrations of β-hydroxybutyrate and carnitine while reducing l-lactate content. The cellular content of phosphoinositide-dependent kinase-1 and hexokinase 2 was reduced consistent with diminished PI3K-AKT signaling and glucose metabolism. The presence of the GLUT8 transporter was established and found to be attenuated by (R,R′)-MNF. Mice treated with (R,R′)-MNF had significant accumulation of l-lactate in tumor tissue relative to vehicle-treated mice, together with reduced levels of the selective l-lactate transporter MCT4. Lower intratumoral levels of EGFR, pyruvate kinase M2, β-catenin, hexokinase 2, and p-glycoprotein were also observed. The data suggest that (R,R′)-MNF reduces glycolysis in PANC-1 cells and tumors through reduced expression and function at multiple controlling sites in the glycolytic pathway.

AB - The Warburg effect is a predominant metabolic pathway in cancer cells characterized by enhanced glucose uptake and its conversion to l-lactate and is associated with upregulated expression of HIF-1α and activation of the EGFR-MEK-ERK, Wnt-β-catenin, and PI3K-AKT signaling pathways. (R,R′)-4′-methoxy-1-naphthylfenoterol ((R,R′)-MNF) significantly reduces proliferation, survival, and motility of PANC-1 pancreatic cancer cells through inhibition of the GPR55 receptor. We examined (R,R′)-MNF's effect on glycolysis in PANC-1 cells and tumors. Global NMR metabolomics was used to elucidate differences in the metabolome between untreated and (R,R′)-MNF-treated cells. LC/MS analysis was used to quantify intracellular concentrations of β-hydroxybutyrate, carnitine, and l-lactate. Changes in target protein expression were determined by Western blot analysis. Data was also obtained from mouse PANC-1 tumor xenografts after administration of (R,R′)-MNF. Metabolomics data indicate that (R,R′)-MNF altered fatty acid metabolism, energy metabolism, and amino acid metabolism and increased intracellular concentrations of β-hydroxybutyrate and carnitine while reducing l-lactate content. The cellular content of phosphoinositide-dependent kinase-1 and hexokinase 2 was reduced consistent with diminished PI3K-AKT signaling and glucose metabolism. The presence of the GLUT8 transporter was established and found to be attenuated by (R,R′)-MNF. Mice treated with (R,R′)-MNF had significant accumulation of l-lactate in tumor tissue relative to vehicle-treated mice, together with reduced levels of the selective l-lactate transporter MCT4. Lower intratumoral levels of EGFR, pyruvate kinase M2, β-catenin, hexokinase 2, and p-glycoprotein were also observed. The data suggest that (R,R′)-MNF reduces glycolysis in PANC-1 cells and tumors through reduced expression and function at multiple controlling sites in the glycolytic pathway.

KW - PKM2

KW - Warburg effect

KW - l-lactate

KW - metabolic reprogramming

KW - metabolomics

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85027111340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027111340&partnerID=8YFLogxK

U2 - 10.1002/ijc.30904

DO - 10.1002/ijc.30904

M3 - Article

C2 - 28741686

AN - SCOPUS:85027111340

VL - 141

SP - 2131

EP - 2142

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -